Clavaseptin 50 mg palatable tablets for dogs and cats

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Amoxicillin; Clavulanic acid

Disponível em:

Vetoquinol Ireland Limited

Código ATC:

QJ01CR02

DCI (Denominação Comum Internacional):

Amoxicillin; Clavulanic acid

Dosagem:

50 mg/tablet

Forma farmacêutica:

Tablet

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Área terapêutica:

amoxicillin and enzyme inhibitor

Status de autorização:

Authorised

Data de autorização:

2005-10-21

Características técnicas

Health Products Regulatory Authority
04 December 2019
CRN0091Q7
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clavaseptin 50 mg palatable tablets for dogs and cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active substances:
Amoxicillin (as amoxicillin trihydrate) 40 mg
Clavulanic acid (as potassium salt) 10 mg
Excipients
Brown iron oxide (E172) 0.095 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
Beige scored tablet that can be divided into two equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs: treatment or adjunctive treatment of periodontal infections
caused by bacteria susceptible to amoxicillin in
combination with clavulanic acid i.e. _Pasteurella _spp.,
_Streptococcus_ spp. and _Escherichia coli_.
In cats: treatment of skin infections (including wounds and abscesses)
caused by bacteria susceptible to amoxicillin in
combination with clavulanic acid i.e. _Pasteurella _spp.,
_Staphylococcus _spp., _Streptococcus _spp. and _Escherichia coli_.
4.3 CONTRAINDICATIONS
Do not use in cases of hypersensitivity to penicillins or other
substances of the β-lactam group or to any of the excipients.
Do not administer to gerbils, guinea pigs, hamsters, rabbits and
chinchillas.
Do not administer to horses and ruminating animals.
Do not use in animals with serious dysfunction of the kidneys
accompanied by anuria or oliguria.
Do not use in cases of known resistance to the combination of
amoxicillin and clavulanic acid.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
In animals with impaired liver and kidney function, the use of the
product should be subject to a risk/benefit evaluation by the
veterinary surgeon and the posology evaluated carefully.
Caution is advised in the use in small herbivores other than those in
4.3.
Use of the product should be based on susceptibil